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Toll-like receptor 7 (TLR7) and TLR9 sense viral nucleic acids and induce type I IFN production,
which must be properly controlled to avoid autoimmune diseases. Here, we report the negative reg-
ulation of TLR7/9-mediated type I IFN production by TRIM35. TRIM35 expression is induced by TLR7/
9 stimulation and then interacts with IRF7, which is the master regulator of type I IFN response.
Furthermore, TRIM35 promotes the K48-linked ubiquitination of IRF7 and induces its degradation
via a proteasome-dependent pathway. Therefore, TRIM35 is a negative feedback regulator of
TLR7/9-mediated type I IFN production due to its ability to suppress the stability of IRF7.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Following viral infection, the innate immune system utilizes
pattern recognition receptors (PRRs) to recognize conserved
pathogen-associated molecular patterns (PAMPs). This triggers a
series of signaling events that lead to the production of inﬂamma-
tory cytokines and type I interferons, such as interferon-a (IFN-a)
and IFN-b [1–3], which are critical for immunity against viruses.
IRF3 and IRF7 are two major transcription factors that induce type
I IFN production [4,5]. IRF3 is activated by TLR3 and TLR4, whereas
IRF7 is activated by TLR7 and TLR9 [6,7]. Although IRF3 expression
is constitutive, the expression of IRF7 is completely dependent on
IFN-a/b signaling and is affected by viral infection and IFNs [5].
Therefore, IRF7 expression must be properly controlled to avoid
excessive activation of the immune response upon viral infection.Despite the importance of IRF7 for host defense against viral
infection, the regulation mechanism of IRF7 remains unclear.
IRF7 has a very short half-life and maintains a low steady-state
level, suggesting that IRF7 may undergo ubiquitin (Ub)-mediated
degradation via the proteasome pathway [4]. At present, several
Ub ligases (E3) that target IRF7 for degradation have been reported.
The Kaposi’s sarcoma-associated herpes virus (KSHV) immediate-
early lytic cycle trigger protein RTA interacts with IRF7, resulting
in a powerful inhibitory effect on IRF7 by targeting it for degrada-
tion in a proteasome-dependent manner [8]. In addition, RAUL
(RTA-associated ubiquitin ligase), a HECT domain ubiquitin (Ub)
E3 ligase, limits type I IFN production by directly catalyzing lysine
48-linked polyubiquitination of both IRF7 and IRF3, followed by
proteasome-dependent degradation [7]. These studies reveal that
a ‘‘brake mechanism’’ for type I IFN production exists and that
IRF7 should be tightly regulated by the Ub-proteasome pathway
to maintain homeostasis.
Tripartite motif TRIM35 (also termed MAIR and Hls5) is a mem-
ber of the TRIM family of single-protein E3 ligases and has an apop-
tosis-inducing function [9]. In addition, TRIM35 is a candidate
tumor suppressor due to its inhibition of cell growth, clonogenic-
ity, and tumorigenicity [10]. In this study, we demonstrated that
TRIM35 expression is highly induced by TLR7 and TLR9 ligands.
Moreover, TRIM35 knockdown promoted type I IFN production
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conﬁrmed by the infection of host cells with the RNA virus vesicu-
lar stomatitis virus (VSV) and the DNA virus herpes simplex virus
type 1 (HSV-1). The mechanism uncovered in this study involves
TRIM35 interacting with IRF7 to induce IRF7 degradation via the
K48-linked ubiquitin-proteasome pathway. These results suggest
that TRIM35 acts as a negative feedback regulator of TLR7- and
TLR9-triggered signaling by targeting IRF7.
2. Results
2.1. Upregulation of TRIM35 expression by TLR7 and TLR9 stimulation
TLRs are type I transmembrane proteins, which mediate the
recognition of their respective PAMPs [11]. TLR signaling must be
well controlled to maintain an appropriate immune response. A
number of TRIM family members have been reported to regulate
TLR signaling pathway [12]. For example, our lab has identiﬁed that
TRIM30a is involved in a negative feedback regulation of TLR4-in-
duced inﬂammatory responses [13]. Besides, TRIM21 interacts with
IRF3 and promotes the ubiquitination and degradation of IRF3 to
limit IFN-b induction downstream of TLR3, TLR4 and RIG-I [14,15].
Considering the important roles of TRIM family in TLR signaling
regulation, we determined to ﬁnd other members involved in this
pathway. So we knocked down the expression of several TRIM fam-
ily members in RAW264.7 cells and treated these cells with TLR7
ligand Resiquimod (R848) and the TLR9 ligand unmethylated
DNA with CpG motifs. Interestingly, we found that TRIM35 knock-
down dramatically enhanced IFN-b induction downstream of R848
and CpG-B DNA stimulation in comparison to other TRIM mole-
cules (Fig. S1). To further verify the function of TRIM35,
RAW264.7 cells were stimulated for different periods of time with
R848 and CpG-B DNA, the results showed that TRIM35 expression
was highly induced on both mRNA and protein levels (Fig. 1). These
results suggest that TRIM35 may play an important role in regula-
tion of TLR7/9 signaling pathways.
2.2. Knockdown of TRIM35 promotes type I IFN and ISGs production
To determine whether TRIM35 is involved in the regulation of
TLR7 and TLR9 signaling, we utilized the knockdown approach to
examine the potential role of TRIM35 in type I IFN production.
Three pairs of siRNA molecules for TRIM35 (T1, T2 and T3) and aFig. 1. TRIM35 is induced by R848 and CpG-B DNA. (A–D) Real-time PCR (A and B) or imm
ml) or CpG-B DNA (1 lg/ml) for various times. b-Actin served as a loading control throug
The values represent the mean ± S.E.M. of more than three experiments. ⁄P < 0.05 and ⁄⁄control siRNA (SC) were designed. After transfection of these
siRNAs, T3 was found to efﬁciently inhibit TRIM35 expression in
HEK293T cells transfected with TRIM35 (Fig. 2A). Furthermore,
we also silenced endogenous TRIM35 expression in RAW264.7
cells and obtained similar results (Fig. 2B). We next selected
siRNA T1 and T3 to knock down TRIM35 in RAW264.7 cells and
then stimulated these cells with R848 or CpG-B DNA for 6 h. The
data showed that TLR7/9 stimuli resulted in a much higher level
of type I IFN and ISGs (IP-10 and Isg56) in cells transfected with
the TRIM35-speciﬁc siRNA (T3) than in those transfected with
the control siRNA or T1 (Fig. 2C). TLR7 and TLR9 also recognize
RNA virus VSV and DNA virus HSV-1, respectively. So we silenced
TRIM35 expression and infected the cells with VSV or HSV-1 for
6 h. Virus infection signiﬁcantly promoted type I IFN and ISGs
induction when TRIM35 was knocked down, which was consistent
with R848 or CpG-B DNA stimulation (Fig. 2D). By contrast, we
detected no difference in the mRNA expression or secreted protein
level of TNF-a, which is a downstream cytokine induced by tran-
scription factor NF-jB (Fig. 2E and F). These data indicate that
TRIM35 plays a negative role in regulating TLR7- and TLR9-trig-
gered type I IFN and ISGs production.
2.3. Knockdown of TRIM35 promotes IFN-b and ISGs production in
pDCs
Plasmacytoid DCs (pDC) selectively express endosomal TLR7
and TLR9. So we determined to investigate the function of
TRIM35 in pDCs. We obtained pDCs by culturing bone marrow cells
in conditioned media containing Flt3 ligand (Flt3L). After 6–8 days,
Flt3L-DCs, which contain largely pDCs, were collected and trans-
fected with control siRNA or TRIM35-speciﬁc siRNA T3 for 24 h.
Two classes of synthetic oligodeoxynucleotides (ODNs), CpG-A
and CpG-B both activate TLR9, but CpG-A induces IFN-a production
much more efﬁciently than CpG-B in pDCs [16,17]. So the TLR9
ligand CpG-A DNA was used to stimulate Flt3L-DCs. The knock-
down and induction effect of TRIM35 were measured at protein
level. The results indicated that endogenous TRIM35 expression
has been reduced by siRNA T3 in comparison to the controls and
CpG-A DNA obviously induced TRIM35 expression (Fig. 3A
and B). Type I IFN, pro-inﬂammatory cytokines and ISGs in the
above DCs were determined by Q-PCR analysis. We observed that
TRIM35 knockdown promoted the levels of type I IFN and IP-10
than that treated with control siRNA after CpG-A DNA stimulation.unoblot analysis (C and D) of TRIM35 in RAW264.7 cells treated with R848 (0.1 lg/
hout the experiment. The mRNA results are relative to those of the untreated cells.
P < 0.01.
Fig. 2. TRIM35 knockdown increases TLR7/9-mediated type I IFN production and ISGs in RAW264.7 cells. (A and B) Immunoblot analysis of the knockdown of exogenous
TRIM35 in HEK293T cells expressing Flag-TRIM35 (A) or of endogenous TRIM35 in RAW264.7 cells (B) treated with control siRNA (SC) or a TRIM35-speciﬁc siRNA (T1, T2, and
T3) for 24 h. RAW264.7 cells were then stimulated for 10 h with CpG-B DNA (1 lg/ml). (C) Real-time PCR analysis of IFN-a6, IFN-b, IP-10 and Isg56 mRNA in RAW264.7 cells
treated with SC, T1 or T3 and stimulated with R848 (0.1 lg/ml) or CpG-B DNA (1 lg/ml) for 6 h, or left untreated. (D) Real-time PCR analysis of IFN-a6, IFN-b, IP-10 and Isg56
mRNA in RAW264.7 cells treated with SC or T3 and then infected with VSV (MOI 1) or HSV-1 (MOI 10) for 6 h, or left untreated. (E and F) Real-time PCR (E) or ELISA (F)
analysis of TNF-a in RAW264.7 cells treated with SC or T3, then stimulated with R848 (0.1 lg/ml) or CpG-B DNA (1 lg/ml), infected with VSV (MOI 1) or HSV-1 (MOI 10) for
6 h (E) or 24 h (F), or left untreated. The mRNA results are relative to those of the untreated cells. The values represent the mean ± S.E.M. of more than three experiments.
⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
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tion (Fig. 3C). Together, these results demonstrate that TRIM35
negatively modulates TLR9 signaling pathway in pDCs.
2.4. TRIM35 interacts with IRF7
To determine the molecular mechanisms by which TRIM35
inhibits type I IFN signaling, we examined the impact of TRIM35
on ISRE promoter-luciferase activation mediated by IRF7 alone orby IRF7 plus TRAF6, which are downstream adaptor molecules of
TLR7 and TLR9. The results showed that TRIM35 overexpression
suppressed IRF7- or IRF7 plus TRAF6-induced activation of the
ISRE promoter (Fig. 4A). TRIM35 also dramatically inhibited the
IRF7-induced activation of ISRE or IFN-a4 in a dose-dependent
manner. Moreover, IFN-a6, the expression of which is only medi-
ated by IRF7, was also suppressed by TRIM35 overexpression
(Fig. 4B), suggesting that TRIM35 functions speciﬁcally at or down-
stream of IRF7.
Fig. 3. TRIM35 knockdown promotes IFN-b and ISGs production in pDCs. (A) Immunoblot analysis of the knockdown of endogenous TRIM35 in Flt3L-DCs treated with control
siRNA (SC) or TRIM35 siRNA T3 for 24 h. The cells were then stimulated for 10 h with CpG-A DNA (2 lg/ml). (B) Immunoblot analysis of the induction of endogenous TRIM35
in Flt3L-DCs stimulated for 12 h with CpG-A DNA (2 lg/ml) or left untreated. (C) Real-time PCR analysis of IFN-a6, IFN-b, IP-10 and TNF-a in Fl3tL-DCs treated with SC or T3
for 24 h, then stimulated for 6 h with CpG-A DNA (2 lg/ml) or left untreated. The mRNA results are relative to those of the untreated cells. The values represent the
mean ± S.E.M. of more than three experiments. ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
Fig. 4. TRIM35 interacts with IRF7. (A) Luciferase activity in HEK293T cells transfected with the empty vector (Vec) or TRIM35 plasmid, together with the indicated plasmids.
(B) Luciferase activity in HEK293T cells transfected with the ISRE promoter, IFN-a4 promoter or IFN-a6 promoter and Vec or increasing amounts of TRIM35 (0.1, 0.2, and
0.4 lg). (C) HEK293T cells were transfected with HA-tagged TRIM35 and Flag-tagged Vector, IRF3 or IRF7, followed by immunoprecipitation with anti-HA Ab (left) or anti-Flag
Ab (right). (D) A schematic representation of TRIM35 and its mutants. (E) Immunoprecipitation and immunoblot analysis of HEK293T cells transfected with TRIM35 deletion
mutants and Flag-IRF7. The values represent the mean ± S.E.M. of more than three experiments. ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
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these two molecules and IRF3 were transfected into HEK293T cells,
and subsequent coimmunoprecipitation experiments revealed that
TRIM35 only interacted with IRF7, not IRF3 (Fig. 4C). Domain map-
ping experiments indicated that only the RING domain of TRIM35
was important for the observed interaction with IRF7
(Fig. 4D and E). Taken together, these results suggest that
TRIM35 can interact with IRF7 and inhibit IRF7-mediated type I
IFN production.2.5. TRIM35 induces K48-linked ubiquitination of IRF7
The TRIM protein family is an expanding family of RING (really
interesting new gene) domain proteins, many of which have ubiq-
uitin E3 ligase activity [18,19]. Although no report to date has indi-
cated that TRIM35 is an E3 ligase in murine or human, it is
interesting to note that in our experiments, TRIM35 markedly pro-
moted IRF7 ubiquitination in HEK293T cells in a dose-dependent
manner, which suggests that TRIM35 may be an E3 ligase
Fig. 5. TRIM35 targets IRF7 for K48-linked ubiquitination. (A) HEK293T cells were transfected with Myc-TRIM35, HA-ubiquitin, or increasing amounts of TRIM35 (0, 1, and
2 lg). Immunoprecipitation and immunoblot analysis were then performed. (B) HEK293T cells were transfected with various combinations of plasmids, followed by
immunoprecipitation with an anti-Flag antibody and immunoblotting with an anti-HA antibody. (C) Immunoassay of HEK293T cells transfected with the indicated plasmids.
(D) Immunoblot analysis of IRF7 ubiquitination in vitro. TRIM35 and IRF7 were translated in vitro, and the ubiquitin, E1 and the indicated E2s were added for ubiquitination
assays. The preparations were incubated at 37 C for 1 h, then immunoprecipitated with anti-myc tag antibody, and analyzed via immunoblot with an anti-Ubi Ab.
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is K48- or K63-linked, we utilized K48-only and K63-only mutant
ubiquitin and found that IRF7 was only modiﬁed by K48-linked
ubiquitin chains (Fig. 5B). As shown in Fig. 5C, wild-type TRIM35
but not TRIM35-DR was able to ubiquitinate IRF7 after transient
transfection, followed by coimmunoprecipitation (Fig. 5C).
To further determine whether TRIM35 directly modiﬁes IRF7,
TRIM35 and IRF7 were translated in vitro, and these two proteins
were mixed with various E2 ligases, ATP and ubiquitin. The prepa-
rations then incubated at 37 C for 1 h, then immunoprecipitated
with anti-myc tag antibody, and analyzed via immunoblot with
an anti-Ubi Ab. We observed that TRIM35 could directly ubiquiti-
nate IRF7 and the E2 UbcH5b showed strong effect of ubiquitination(Fig. 5D). Together, these data indicate that TRIM35 induces the
K48-linked ubiquitination of IRF7 via its RING domain.
2.6. TRIM35 promotes the degradation of IRF7
Because K48-linked ubiquitin chains are believed to be the prin-
cipal signal for targeting substrates for degradation by the protea-
some, we next investigated whether TRIM35 targets IRF7 for
degradation [20,21]. Endogenous TRIM35 was knocked down in
RAW264.7 cells, which were then stimulated for different times
with R848 or CpG-B DNA. The results showed that IRF7 protein
levels were higher in the TRIM35-silenced cells compared with
the control cells, suggesting that TRIM35 may promote IRF7
Fig. 6. TRIM35 increases the degradation of IRF7. (A and B) Immunoblot analysis of IRF7 and IRF3 of RAW264.7 cells transfected with control siRNA (SC) or TRIM35-speciﬁc
siRNA (T3) and then stimulated with R848 (0.1 lg/ml) (A) or CpG-B DNA (1 lg/ml) (B) for the indicated times. Densitometry analysis of IRF7 or TRIM35 is shown on the right.
(C and D) RAW264.7 cells were transfected with the indicated siRNAs, stimulated with R848 (0.1 lg/ml) (C) or CpG-B DNA (D) (1 lg/ml) for 8 h, and then fractionated into
nuclear and cytosolic subfractions. IRF7 and IRF3 were analyzed by immunoblot analysis. (E) Immunoblot analysis of IRF7 in RAW264.7 cells stimulated with CpG-B DNA for
the indicated time periods in the absence or presence of 20 lMMG132. (F and G) Immunoassay of HEK293T cells transfected with various combinations of plasmids and then
treated for 6 h with DMSO or 20 lMMG132. (H) Luciferase activity of HEK293T cells transfected with the IFN-a4 promoter, empty vector (Vec), TRIM35 (FL) or TRIM35 (DR),
together with IRF7. The values represent the mean ± S.E.M. of more than three experiments. ⁄⁄⁄P < 0.001.
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mRNA level in RAW264.7 cells stimulated with R848 or CpG-B
DNA and found that TRIM35 knockdown did not promote IRF7
transcription (Fig. S2). Furthermore, the presence of IRF7 protein
in nuclear and cytoplasmic extracts was relatively enhanced in
the TRIM35-silenced cells compared with their counterpart con-
trols (Fig. 6C and D).
IRF7 remains at low levels in most cell types and has a very short
half-life in infected cells, yet it can be stabilized by the 26S protea-
some inhibitor MG132 [22]. Consistent with these ﬁndings, weobserved that IRF7 expression was maintained at a high level in
RAW264.7 cells after treatment with MG132, whereas IRF7 was
found to be degraded at 12 h in control cells (Fig. 6E). HEK293T cells
were then transfected with plasmids expressing Flag-IRF7, HA-
ubiquitin or Myc-TRIM35, and we found that IRF7 was dramatically
degradedwhen coexpressed with TRIM35. However, this effect was
attenuatedwhen the cells were treatedwithMG132 (Fig. 6F). As the
RING domain confers E3 ligase activity to TRIM35, TRIM35-DR
attenuated this degradation of IRF7 (Fig. 6G). In addition, TRIM35-
DR did not inhibit the IRF7-induced activation of the IFN-a4
1328 Y. Wang et al. / FEBS Letters 589 (2015) 1322–1330promoter (Fig. 6H). These results reveal that TRIM35 targets IRF7
for degradation via its RING domain and that this effect can be sup-
pressed by the proteasome inhibitor MG132.
3. Discussion
In this study, we determined that TRIM35 was induced upon
TLR7 and TLR9 stimulation and that it negatively regulates this
pathway. Furthermore, the knockdown of TRIM35 enhanced type
I IFN production following TLR7 and TLR9 stimulation. Our results
showed that TRIM35, which is an E3 ligase, can interact with IRF7
and promote its K48-dependent ubiquitination and subsequent
proteasome-dependent degradation. Thus, TRIM35 is involved in
the negative-feedback loop that turns off or abrogates excessive
type I IFN production because it targets the central transcription
regulator IRF7.
Type I IFN production must be tightly regulated because the
excessive expression of type I IFN results in many types of diseases,
such as systemic lupus erythematosus, Sjögren’s syndrome and
multiple sclerosis [23–25]. The regulation of IRF7 is one of the
mechanisms that maintains type I IFN production at an appropriate
level. The 20-50-oligoadenylate produced by the 20-50-oligoadeny-
late synthetase (OAS) OASL1 inhibits the translation of IRF7
mRNA by binding to its 50 untranslated region (UTR), thus nega-
tively regulating the robust production of type I IFN during viral
infection [26]. Moreover, IRF7 also undergoes various posttransla-
tional modiﬁcations (PTMs), such as phosphorylation, ubiquitina-
tion, SUMOylation and acetylation [22].
Indeed, protein ubiquitination has emerged as a key mechanism
that regulates immune responses [27]. The HECT domain ubiquitin
E3 ligase RAUL limits type I IFN production by directly catalyzing
the Lys48-linked polyubiquitination of both IRF7 and IRF3, fol-
lowed by proteasome-dependent degradation. Moreover, TRIM21
(also known as Ro52 and SSA1) interacts with IRF7 and promotes
IRF7 ubiquitination and degradation [28]. Together, these ubiquitin
ligases likely orchestrate an appropriate immune response, helping
to prevent the host from autoimmune diseases. TRIM35, which
was ﬁrst identiﬁed as an E3 ligase in murine, participates in the
feedback system that limits the robust immune response.
Therefore, TRIM35 is an important negative regulator of the
TLR7- and TLR9-dependent pathway in response to nucleic acid
stimulation or viral infection.
PDCs, also known as type I IFN-producing cells, selectively
express endosomal TLR7 and TLR9 [29,30]. In this report, we
deﬁned the negative role of TRIM35 in moderating TLR9 signaling
pathway in pDCs, which suggesting the important function TRIM35
in maintaining the homeostasis of immune response.
In summary, we identiﬁed a new regulator, TRIM35, of the type
I IFN pathway upon stimulation of TLR7 and TLR9, and we found
that TRIM35 plays an important role in the negative-feedback loop
of this pathway. First, TRIM35 protein expression is induced by
TLR7 and TLR9 activation, and TRIM35 knockdown considerably
enhances type I interferon production. Second, TRIM35 interacts
with IRF7, and TRIM35 overexpression suppresses the IRF7-in-
duced activation of ISRE or an IFN-a4/6 reporter. Finally, TRIM35
promotes K48-linked ubiquitination of IRF7 and induces its degra-
dation via a proteasome-dependent pathway.
4. Materials and methods
4.1. Mice
C57BL/6 mice were purchased from the Shanghai Laboratory
Animal Center (SLAC). All mice were bred and kept in speciﬁc
pathogen-free (SPF) conditions in the Shanghai Institute ofBiochemistry and Cell Biology. All animal experiments were con-
ducted in accordance with institutional guidelines at the
Shanghai Institutes for Biological Sciences (Chinese Academy of
Sciences).
4.2. Plasmid constructs and reagents
Mouse TRIM35 was ampliﬁed by PCR using cDNA from CpG-B
DNA-stimulated bone marrow-derived dendritic cells (BMDCs)
and subsequently cloned into the pcDNA3 vector (Invitrogen). All
TRIM35 and IRF7 deletion mutants were ampliﬁed by PCR and then
subcloned into pcDNA3. The HA-K48-ubi and HA-K63-ubi plasmids
were kindly provided by Hongbing Shu (Wuhan University,Wuhan,
China). Other plasmids were generated or obtained as described
previously [31]. CpG-A DNA (tlrl-1585) and CpG-B DNA (tlrl-
1668) was obtained from Invivogen, and R848 (SML0196) was
obtained from Sigma-Aldrich. A polyclonal Ab against IRF7 (anti-
IRF7) was generated as described previously [31]. The anti-c-Myc
Ab was obtained from Amyjet Scientiﬁc Inc (A02060), anti-HA Ab
was obtained from Covance (HA.11; 16B2; CO-MMS-101R), and
the anti-Flag (M2; F3165) and anti-b-actin (A2066) Abs were pur-
chased from Sigma–Aldrich. The anti-TRIM35 (SC-79787) Ab, the
anti-IRF3 (sc-9082) Ab and the anti-SP1 (sc-59) Ab were purchased
from Santa Cruz Biotechnology. The anti-a-tubulin (2144) Ab was
obtained from Cell Signaling Technology. Flt3 ligand (Flt3L) was
purchased from peproTech. HSV-1 was kindly provided by X. Cao
(Second Military Medical University, Shanghai, China).
4.3. Cell culture and transfections
HEK293T, L929 and RAW264.7 cells were cultured in DMEM. All
of the media were supplemented with 10% FBS (Invitrogen), 4 mM
L-glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin, and
the cells were placed at humidiﬁed conditions with 5% CO2 at
37 C. HEK293T and RAW264.7 cells were transfected with
Turbofect (Thermo Scientiﬁc) or Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. X-tremeGENE
(Roche) was used for the transient transfection of plasmid DNA
into L929 cells.
4.4. RNA interference
TRIM35-Stealth-RNA interference was designed by the
Invitrogen BLOCKiT RNAi Designer. The small interfering RNA
(siRNA) sequences used were as follows:
T1, forward, 50-CCUGGCUUGCUAAUGGAUGCAUGCA-30, reverse,
50-UGCAUGCAUCCAUUAGCAAGCCAGG-30; T2, forward, 50-UCUGU
AUACCUUCCAUGCCCACUUU-30, reverse, 50-AAAGUGGGCAUGGAA
GGUAUACAGA-30; T3, forward, 50-CCUGCCUGCUAGGCUCUCAAGU
GUU-30, reverse, 50-AACACUUGAGAGCCUAGCAGGCAGG-30.
RAW264.7 cells were transfected with siRNA using
Lipofectamine 2000 according to the manufacturer’s instructions.
The cells were used for experiments at 24 h after transfection.
4.5. ELISA
The levels of mouse TNF-a in the supernatants were determined
using TNF-a (eBioscience) ELISA kits, according to the manufactur-
ers’ instructions.
4.6. Generation of pDCs
Bone marrow cells were collected from the femurs and tibias of
C57BL/6 mice. Bone marrow cells were cultured in RPMI 1640 con-
taining 10% FBS, 10 mMHEPES (pH 7.4), 50 lM b-mercaptoethanol,
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were collected and used as Flt3L-induced BMDCs (pDC).
4.7. Reporter gene assay
HEK293T cells were transfected with reporter plasmids and a
Renilla luciferase plasmid as an internal control plus the indicated
expression plasmids. The total DNA concentration was kept con-
stant by making up the difference with the empty pcDNA3 vector.
Twenty-four hours after transfection, the cells were lysed in pas-
sive lysis buffer, and the luciferase activity in the lysates was ana-
lyzed with a dual luciferase reporter assay system (Promega).
4.8. Immunoprecipitation and immunoblot analysis
Immunoprecipitation and immunoblot analysis were per-
formed as described previously [13]. Brieﬂy, HEK293T or L929 cells
were transfected with various combinations of plasmids. Twenty-
four hours after transfection, the cell lysates were prepared in lysis
buffer and incubated with the indicated Abs together with protein
A/G Plus-agarose immunoprecipitation reagent (Santa Cruz
Biotechnology) at 4 C for 4 h or overnight. After three washes,
the immunoprecipitates were boiled in SDS sample buffer for
10 min and analyzed by immunoblotting.
4.9. In vitro ubiquitination assay
TRIM35 and IRF7 proteins were expressed with a TNT Quick-
coupled Transcription/Translation Systems kit (Promega). In vitro
ubiquitination assay was performed with a ubiquitination kit
(Enzo Life Science) following the manufacturer’s instructions.
4.10. Nuclear extracts
The nuclear extracts were prepared as described previously
[32].
4.11. Real-time PCR
Total RNA was extracted from the cultured cells with TRIzol
reagent (Invitrogen), and the cDNA was prepared as described pre-
viously [13]. All gene transcripts were quantiﬁed by real-time PCR
with the SYBR Green qPCR Master Mix using a 7500 Fast real-time
PCR system (Applied Biosystems). The relative fold induction was
calculated using the 2DDCt method. The primers used for real-time
PCR were as follows:IFN-a6: Forward, 50-AGCTACTGGTCAACCTGCTCTCTAG-30 ,
Reverse, 50-CCAGGAGTGTCAAGGCTTTCTT-30;IFN-b: Forward, 50-AGTGTCAGAAGCTCCTGTGGC-30 ,
Reverse, 50-TGAGGCAGTATTCAAGCCTCC-30;IP-10: Forward, 50-GGGCCAGTGAGAATGAGGG-30 ,
Reverse, 50-GCTCGCAGGGATGATTTCAA-30;Isg56: Forward, 50-CTCAGAGCAGGTCCAGTTCCTT-30 ,
Reverse, 50-GGCCAGGAGGTTGTGCAT-30;TNF-a: Forward, 50-ATGAGCACTGAAAGCATGATCC-30 ,
Reverse, 50-GAGGGCTGATTAGAGAGAGGTC-30;HPRT: Forward, 50-TGCTCGAGATGTCATGAAGGAG-30 ,
Reverse, 50-CAGAGGGCCACAATGTGAT-30.4.12. Statistics
All data are presented as the mean ± S.E.M. from at least three
independent experiments. The statistical comparisons betweenthe different treatments were performed using the unpaired
Student t test, and P < 0.05 was considered statistically signiﬁcant.
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